RARS1
protein-codingarginyl-tRNA synthetase 1, the group of Aminoacyl tRNA synthetases, Class I
Gene summary
Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Arginyl-tRNA synthetase belongs to the class-I aminoacyl-tRNA synthetase family. [provided by RefSeq, Jul 2008]
- RARS
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~32.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0014506
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0014506
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0014506
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0014506
Submitter: ClinGen
RARS1 was first reported in relation to autosomal recessive hypomyelinating leukodystrophy 9 in 2014 (Wolf et al, 2014 PMID:24777941). Reported phenotypes include spasticity, nystagmus, delayed development, intellectual disability (mild to severe), hypertonicity, ataxia, dysmetria, dysarthria, tremoring, and hypomyelination on brain MRI (Wolf et al, 2014 PMID:24777941). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanisms or inheritance pattern. Therefore, there is one disease entity, hypomyelinating leukodystrophy 9 (OMIM: 616140). 29 variants (12 putative null (4 start codon, 4 fs, 4 splice), 16 missense, 1 in-frame deletion) that have been reported in 40 patients in 11 publications (PMID:24777941, 30791064, 28905880, 31814314, 40594583, 33190326, 38618971, 30500859, 39762984, 37186453, 29451896). 9 probands and 5 publications are included in the genetic evidence of this curation. More evidence is available in the literature, and a maximum score of 12 for genetic evidence has been reached (max 12). The mechanism of pathogenicity is reported to be loss of function (Li 2021, PMID33515434). This gene-disease relationship is also supported by a knockout zebrafish model (Kim 2025 PMID: 39762984). In summary, there is definitive evidence supporting the relationship between RARS1 and autosomal recessive hypomyelinating leukodystrophy 9, also known as RARS1-related hypomyelinating leukodystrophy. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Leukodystrophy and Leukoencephalopathy GCEP on the meeting date December 22, 2025 (SOP Version 11). Curation scoring was updated to reflect SOP Version 12 changes.
Inheritance Pattern: Unknown
Disease ID:MONDO:0014506
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0014506
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0014506
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0014506
Submitter: Laboratory for Molecular Medicine
This gene-disease relationship has undergone rapid assessment. Classifications are based on preliminary review of gene-disease validity during analysis of genomic sequencing results.
Clinical Genomic Database (CGD)
Manifestation: Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to RARS1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_002887.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 2 | 49 | 51 | |||
| missense | 1 | 6 | 173 | 11 | 1 | 192 |
| nonsense | 5 | 6 | 11 | |||
| start loss | 4 | 1 | 5 | |||
| frameshift | 7 | 7 | 3 | 17 | ||
| splice donor/acceptor (+/-2bp) | 1 | 4 | 2 | 7 | ||
| Total | 18 | 24 | 180 | 60 | 1 | 283 |
Highest pathogenic variant AF is 0.000028225068
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_002878.2 | 15 | MANE Select | |
| Ensembl | ENSP00000231572.3 | 15 | MANE Select | |
| Ensembl | ENSP00000429030.1 | 4 | Standard | |
| Ensembl | ENSP00000428494.1 | 3 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Aminoacyl-tRNA biosynthesis - Homo sapiens (human)
- miR-targeted genes in epithelium - TarBase
- miR-targeted genes in lymphocytes - TarBase
- miR-targeted genes in muscle cell - TarBase
- miR-targeted genes in squamous cell - TarBase
Biological Process
- tRNA aminoacylation for protein translation
- arginyl-tRNA aminoacylation
Molecular Function
- tRNA binding
- arginine-tRNA ligase activity
- protein binding
- ATP binding
- arginine binding
Cellular Component
- nucleus
- nucleoplasm
- cytoplasm
- cytosol
- membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000231572
- Coding exons
- 15
- Length
- 32855
- Individuals with no LoFs
- 125671
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 77
- Defined
- 125748
- p
- 0.000306
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.544 | 319 | 348 | 0.918 | 0.0000175 | 4343 |
| Missense (PolyPhen) | 138 | 154.64 | 0.8924 | 1891 | ||
| Synonymous | 0.192 | 116 | 119 | 0.978 | 0.00000547 | 1210 |
| Loss of Function | 2.64 | 18 | 34.8 | 0.517 | 0.00000188 | 437 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00044 | 0.00043 | rare |
| Latino/Admixed American | 0.00041 | 0.00038 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00044 | 0.00044 | rare |
| Finnish | 0.00037 | 0.00037 | rare |
| European (Non-Finnish) | 0.00032 | 0.00030 | rare |
| South Asian | 0.00020 | 0.00020 | rare |
| Other | 0.00016 | 0.00016 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Forms part of a macromolecular complex that catalyzes the attachment of specific amino acids to cognate tRNAs during protein synthesis (PubMed:25288775). Modulates the secretion of AIMP1 and may be involved in generation of the inflammatory cytokine EMAP2 from AIMP1 (PubMed:17443684). {ECO:0000269|PubMed:17443684, ECO:0000269|PubMed:25288775}.;
- Disease
- DISEASE: Leukodystrophy, hypomyelinating, 9 (HLD9) [MIM:616140]: An autosomal recessive neurodegenerative disorder characterized by delayed psychomotor development, severe spasticity, nystagmus, and ataxia associated with diffuse hypomyelination apparent on brain MRI. {ECO:0000269|PubMed:24777941}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.412
Intolerance Scores
- LoFtool
- 0.872
- RVIS EVS
- -0.42
- RVIS percentile EVS
- 25.64
Essentials
- Essential (CRISPR)
- E
- Essential (CRISPR2)
- E
- Essential (gene trap)
- E
- Indispensability pred.
- E
- Indispensability score
- 0.993
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |